General discussion, page-4143

An excellent couple of days for all shareholders, new and old. Technically this is setting up like a dream IMO, progressively higher levels of support and sustainable volume and price.

This is not a “flash in the pan” company nor are the price movements. It’s the product of all the strategic planning and progress implemented during the previous year by a disciplined and aligned Board of Directors and Medical Advisory Board.

There are very solid fundamentals driving investor interest and IMO we are entering a high growth phase with potential for the share price to move substantially higher.

The building blocks have been carefully laid for 3 rapidly advancing clinical trials and one psychedelic trial. Each of these clinical conditions are potentially company making events. Additionally the market cap is also at a point where the company will be receiving interest from serious professional money, the type that will create a base at these levels and drive the business further and price higher.

I have every expectation that LT term shareholders will be rewarded as we anticipate a smorgasbord of news flow that could be announced at any time. Very exciting period, GLTAH.